Paragon Care Limited (PGC) AI Stock Analysis

• Market Cap: €579.36M
• Dividend Yield: N/A
• Average Volume (3M): 814.70K
• Price to Earnings (P/E): 28.8
• Beta (1Y): 1.01
• Revenue Growth: 1387.97%
• EPS Growth: -1.57%
• Country: AU
• Employees: 400
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Distribution
• EPS (TTM): 0.80
• Shares Outstanding: 1,655,305,400
• 10 Day Avg. Volume: 813,472
• 30 Day Avg. Volume: 814,699
• PEG Ratio: 1.16
• Price to Book (P/B): 2.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -246.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.52
• Price Target Upside: 44.53% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 58 Neutral
• Price Target: AU$0.50 ▲(38.89%Upside)

Paragon Care Limited's stock score is primarily supported by its solid financial performance, especially strong cash flow management. However, the bearish technical indicators and relatively high P/E ratio suggest caution. The lack of a dividend yield further tempers the valuation attractiveness.

Paragon Care Limited Business Overview & Revenue Model

Company Description

Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, biologics, and the operating room; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for surgical procedures such as neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care diagnostics, therapeutic lasers, oncology delivery products, centrifuges, autoclaves, IV lines and fluid therapy products, wearable CRI systems, and IT Solutions. Further, it provides telephony, nurse call, access control, CCTV, cordless, and Wi-Fi products. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. Paragon Care Limited was incorporated in 1994 and is based in Melbourne, Australia.

How the Company Makes Money

Paragon Care Limited generates revenue through the sale of medical equipment, devices, and consumables to hospitals, healthcare providers, and other medical institutions. The company also offers maintenance and support services for its products, providing an additional revenue stream. Key revenue streams include direct sales of their diverse range of healthcare products, long-term supply contracts, and partnerships with leading international manufacturers, which enable Paragon Care to distribute high-quality, innovative products across the Asia-Pacific region. The company's strategic acquisitions and partnerships help expand its product offerings and market reach, contributing significantly to its financial performance.

Paragon Care Limited Financial Statement Overview

Summary

Paragon Care Limited demonstrates a solid financial performance with consistent revenue growth and effective cash flow management. While the company faces some profitability challenges, its balanced leverage and cash generation capabilities provide a stable foundation for future growth.

Income Statement

Paragon Care Limited has shown a stable revenue growth trajectory over recent years with a revenue increase in the TTM period. Despite a dip in net income, the company maintains solid profit margins with a Gross Profit Margin of 5.93% and an EBIT Margin of 1.63% in the latest annual report. However, the decline in EBITDA and net income in the latest TTM period suggests profitability challenges remain.

Balance Sheet

The company demonstrates a moderate Debt-to-Equity Ratio of 0.86, reflecting a balanced leverage level. A positive Return on Equity of 2.87% indicates effective use of equity, albeit lower compared to previous periods. The Equity Ratio is 25.81%, showing a stable financial structure with room for improvement.

Cash Flow

Paragon Care Limited has exhibited strong cash flow management with significant Free Cash Flow growth, albeit from a negative base in the previous year. The Operating Cash Flow to Net Income ratio of 5.30 indicates strong cash generation relative to accounting profit, enhancing financial flexibility.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	4.66B	2.97B	307.63M	237.62M	235.84M	231.69M
Gross Profit	230.97M	176.07M	51.68M	36.58M	33.41M	78.76M
EBITDA	75.74M	43.18M	37.07M	23.27M	20.18M	-62.09M
Net Income	18.67M	8.38M	10.76M	6.63M	8.28M	-77.27M
Balance Sheet
Total Assets	1.24B	1.13B	448.52M	438.44M	291.92M	292.17M
Cash, Cash Equivalents and Short-Term Investments	21.66M	19.94M	22.60M	46.20M	33.20M	24.50M
Total Debt	299.90M	251.83M	122.14M	131.26M	113.01M	115.03M
Total Liabilities	927.81M	838.97M	196.56M	196.31M	170.40M	179.89M
Stockholders Equity	310.96M	291.92M	242.85M	235.82M	121.52M	112.28M
Cash Flow
Free Cash Flow	-2.93M	25.14M	-3.30M	14.42M	22.18M	-1.98M
Operating Cash Flow	2.38M	44.45M	17.75M	19.03M	27.46M	5.29M
Investing Cash Flow	-3.77M	-19.52M	-31.75M	7.07M	-18.80M	-11.40M
Financing Cash Flow	12.93M	-5.95M	-10.00M	-11.93M	32.00K	-3.60M

Paragon Care Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PGC, the sentiment is Negative. The current price of 0.36 is below the 20-day moving average (MA) of 0.39, below the 50-day MA of 0.40, and below the 200-day MA of 0.45, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 34.59 is Neutral, neither overbought nor oversold. The STOCH value of 12.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PGC.

Paragon Care Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PGC	58 Neutral	€579.36M	28.80	6.68%	―	1387.97%	-1.57%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.34%	16.99%	1.69%
ANSLF		$2.88B	22.01	6.45%	2.46%	―	―
CHEOF		$12.62B	51.72	20.61%	1.46%	―	―
CMXHF		$74.12B	26.93	15.38%	1.65%	―	―
RMSYF		$5.42B	1,144.55	0.52%	2.00%	―	―
SHL	73 Outperform	AU$12.56B	22.96	6.86%	3.36%	10.15%	6.20%

Paragon Care Limited Corporate Events

Paragon Care Appoints Carmen Riley as New CEO

Paragon Care Limited has announced the appointment of Carmen Riley as the new Chief Executive Officer, effective July 1, 2025. This transition follows the successful merger of Oborne, ParagonCare, and Clifford Hallam Healthcare Pty Ltd (CH2), and aligns with the company’s long-term growth strategy. Carmen Riley, who has been with CH2 for 15 years and served as Chief Operating Officer, will take over from David Collins, who will remain as Managing Director until June 2026. This leadership change is expected to bolster Paragon Care’s growth prospects and enhance shareholder equity, with David Collins focusing on mergers and acquisitions during the transition period.

The most recent analyst rating on (AU:PGC) stock is a Buy with a A$0.52 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Limited Announces Change in Substantial Holder Voting Power

Paragon Care Limited has reported a change in the voting power of its substantial holder, Wilson Asset Management Group, which has increased from 6.19% to 7.45%. This change in voting power indicates a shift in the control dynamics within the company, potentially impacting decision-making processes and stakeholder interests.

The most recent analyst rating on (AU:PGC) stock is a Buy with a A$0.52 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Limited Updates Securities Trading Policy

Paragon Care Limited has announced a revision to its Securities Trading Policy, aligning with ASX Listing Rule 12.10. This update reflects the company’s commitment to maintaining robust corporate governance practices. The revised policy is accessible on the company’s website, underscoring Paragon Care’s dedication to transparency and regulatory compliance, which is crucial for its stakeholders and market positioning.